Queensland-based businesses can access grants of up to $250,000 to develop biomedical products locally.
The latest round of grants through the Queensland Biomedical Attraction Program (QBBAP) is aimed at attracting more interstate and international biomedical projects to the state, which has a goal of being a globally competitive Asia-Pacific biomedical industry hub by 2027.
This is the fourth QBBAP funding round and previous recipients include:
- QUT conducted a preclinical study for an interstate client in the development of a type 1 diabetes treatment.
- Microba, a microbiome research support company, is using its grant to provide clinical study services to an international client. This has helped it attract new clients in the in the emerging field of microbiome-targeting therapies, which play a key role in many aspects of health and disease.
- The University of Queensland attracted national and international clients to its state-of-the-art laboratories providing custom manufacturing solutions to develop next generation complex therapies e.g. protecting pets and livestock from paralysis tick toxins.
- AnteoTech entered an agreement with an international company for the joint production and marketing of a novel diagnostic solution.
- Patheon Biologics, which manufactures complex innovative drugs from cells, secured a new international client through the grant.
Grants are available up to one-third of the service costs of developing a biomedical product.
The deadline for this round of funding is May 31, 2024. Visit the Queensland Biomedical Attraction Program site for more information.
